$168.13
0.190.11%
Dern. MÀJ: Nov 13, 11:57 AM
Gilead Sciences rose 34.1% from $125.20 to $167.95, ahead of the S&P 500's +12.7%. Its worst day was Nov 5 (−4.0%), and its low came Jan 5 at $118.30.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Gilead Sciences closed at its lowest level of the year, 5.5% below where the year started.
−2.7% · S&P 500 +0.7%
EPS of $1.86 beat the $1.83 estimate on $7.9B revenue (est. $7.6B); FY revenue guidance of $29.6B–$30.0B against the $30.1B consensus.
Story events cover the past 12 months · Times ET
+5.8%, the year's best day · S&P 500 0.0%
EPS of $2.03 beat the $1.91 estimate on $7.0B revenue (est. $6.9B); FY revenue guidance of $30.0B–$30.4B against the $30.2B consensus.
−2.0% · S&P 500 +0.8%
Gilead Sciences shares rose 5.2%, while the S&P 500 fell 0.5%.
+5.2% · S&P 500 −0.5%
EPS of $-6.75 beat the $-7.14 estimate on $7.8B revenue (est. $7.4B); FY revenue guidance of $30.1B–$30.4B against the $30.5B consensus.
−2.6% · S&P 500 −0.2%
EPS of $2.55 beat the $2.18 estimate on $8.3B revenue (est. $7.8B); FY revenue guidance of $31.0B–$31.3B against the $30.8B consensus.
+3.1% · S&P 500 −1.8%
Where it ended: a close of $167.95 on Nov 12, 2026. Up next: Q4 2026 earnings on Feb 9, 2027 (EPS est. $1.16, revenue est. $8.3B).
As of the Nov 12, 2026 close
Replay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GILD and SPY from Benzinga historical bars. Not investment advice.